Novo Nordisk A/S

By default your notes are visible only to you.

35.1

52-week range

81.4

45.58

Your model inputs

Required return / cost of capital

FCFF terminal growth rate

Your fair value & Margin of safety

To calculate fair value based on cost of capital and terminal growth assumptions above, please select free cash flow forecast.

Forecast:

Valuation

Free Cash Flow Yield

FCF Yield TTM = Trailing Twelve Months free cash flow per share / current market price per share

15.3 %

Dividend Yield TTM

4 %

Market cap $

$ 202,548

Price / Earnings TTM

P/E TTM = current market price per share / Trailing Twelve Months diluted earnings per share

1.7

Price / Book TTM

6.4

PEG TTM

Price/Earnings-to-Growth ratio = P/E TTM divided by most recent annual diluted earnings per share growth rate

0.9

Earnings growth and return

LTM

5YR

10YR

Total return (price & dividends)

(31.9) %

30.1 %

96.6 %

Free cash flow per share growth

(58.2) %

2.1 %

5.4 %

Earnings per share growth

1.8 %

155.6 %

240.7 %

Founded: 1,923

Employees: 69,260

Business Summary:Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Fair Value Reference Estimate